

Supporting Information for

The Development of a High-Affinity Conformation-Sensitive Antibody  
Mimetic Using a Biocompatible Copolymer Carrier (iBody)

Blažková K.<sup>[a],[b]</sup>, Beranová J.<sup>[a],[c]</sup>, Hradilek M.<sup>[a]</sup>, Kostka L.<sup>[d]</sup>, Šubr V.<sup>[d]</sup>, Etrych T.<sup>[d]</sup>, Šácha P.<sup>\*[a]</sup> and  
Konvalinka J.<sup>\*[a],[b]</sup>

**Contents:**

Supplemental figure S1: Changes in phage titre of the phage pool after each round of selection.

Supplemental figure S2: The comparison of lead peptides from repeated selection using library A cyclized by TBMB panned against PSMA


Supplemental figure S3: Gel permeation chromatography (GPC) chromatogram of polymer precursor and polymer conjugate iBody 1.

Supplemental figure S4: Structures of PSMA inhibitors JB-395d, JB-352 and 2-PMPA.

Supplemental figure S5: Gating used for flow cytometry experiments

Supplemental figure S6: Competition of small molecular inhibitors 2-PMPA and phosphate with the binding of iBody 1 on cells expressing PSMA and control cells.


Supplemental table ST1: Comparison of specific binding of iBody 1 to PSMA or control layer (without PSMA) on ELISA compared to iBody 3 (not targeted to PSMA).






Supplemental figure S1: Changes in phage titre of the phage pool after each round of selection. Samples from each pool from positive selection or control selection were analyzed using titration assay and determined phage titres were plotted. The increase in phage titre in selection done on PSMA+ beads over control PSMA- beads correlates to the amplification of binding clone.

MAACDDECPDYVCGGSG	258006	MAACDDECPDYVCGGSG	144664	MAACDDECPDYVCGGSG	247048
MAACPPLCAKWQCGGSG	25096	MAACHRQCFLSWCGGSG	57642	MAACHRQCFLSWCGGSG	7928
MAACRRADICTLDCGGSG	13698	MAACRRADICTLDCGGSG	19303	MAACRRADICTLDCGGSG	6023
MAACRSFVFNIDCGGSG	5461	MAACPPLCAKWQCGGSG	8254	MAACVLKCVGDNDCGGSG	2951
MAACRSASVCSIDCGGSG	1846	MAACVTWYCSSNYCGGSG	1692	MAACAKQCFLSWCGGSG	1282
MAACAKQCFLSWCGGSG	922	MAACQYAYDCDLPCGGSG	683	MAACSHTCIMHSHCGGSG	859
MAACHRQCFLSWCGGSG	556	MAACRSAAVCNLPCGGSG	529	MAACRSAAVCNLPCGGSG	728
MAAWLEQLRGDHSFGGSG	141	MAACPYIECLYQPCGGSG	181	MAACHAHCLHSIPCGGSG	726
MAACHQHPCIHMC GGSG	92	MAACYQLCWWGWCGGSG	177	MAACDHRCHKHIQCGGSG	598
MAACHSQFHCEPRCGGSG	68	MAACDDECFLSWCGGSG	121	MAACRRHCSMHTCGGSG	478
Total reads	333886	Total reads	255629	Total reads	294511


Supplemental figure S2: The comparison of lead peptides from repeated selection using library A cyclized by TBMB panned against PSMA. Peptides with identical or highly similar motifs are highlighted. Top 10 most abundant sequences after translation and quality control (fixerr function=10) are shown from each selection. Peptides with HPQ binding motif (Streptavidine binders), peptides with even number of cysteins and peptides without GGSG linker are not shown.




Supplemental figure S3. Gel permeation chromatography (GPC) chromatogram of polymer precursor (grey) and polymer conjugate iBody 1 (blue). Curves were obtained from dRI detector.



Supplemental figure S4. Structures of PSMA inhibitors JB-395d (compound 1 in Šácha et al., 2016), JB-352 (compound 3 in Tykvart et al., 2014) and 2-PMPA.



Supplemental figure S5. Gating used for flow cytometry experiments depicted in Figure 5 A) and B). Analogous gating was used for Supplemental figure S6. Main cell population was gated first, followed by gating for single cells.



Supplemental figure S6: Competition of small molecular inhibitors 2-PMPA and phosphate with the binding of iBody 1 on cells expressing PSMA and control cells. U251 PSMA-transfected cells (PSMA+) and control untransfected U251 cells were harvested and incubated in TBS with 500 nM iBody 1 and with either 500 nM 2-PMPA (purple), 5mM  $\text{KH}_2\text{PO}_4$  (turquoise) or TBS (positive control, grey).

Supplemental table ST1: Comparison of specific binding of iBody 1 (targeted to PSMA through the bicyclic peptides) to PSMA or control layer (without PSMA) on ELISA compared to iBody 3 (not targeted to PSMA). iBody 1 titration was done in duplicates, while iBody 3 titration was done in triplicate. Chemiluminescence was measured and values obtained for individual points were averaged and are shown in ST1 below in relative light units (RLU). Ratio was calculated for each concentration point of each iBody as value on layer with PSMA divided by the value for the same sample incubated on the layer lacking PSMA.

	concentration of iBody 1 (nM)				
	5000	1000	200	40	8
with PSMA	6373850	5914050	5048350	4164800	2978900
w/o PSMA	5500250	2193900	493730	84709	11632
Ratio:	1.2	2.7	10.2	49.2	256.1

	concentration of iBody 3 (nM)				
	5000	1000	200	40	8
with PSMA	132297	39446	13557	3449	2241
w/o PSMA	156303	46668	12845	2571	2423
Ratio:	0.8	0.8	1.1	1.3	0.9

Supplement references:

- [1] P. Šácha, T. Knedlík, J. Schimer, J. Tykvart, J. Parolek, V. Navrátil, P. Dvořáková, F. Sedlák, K. Ulbrich, J. Strohalm, et al., *Angew. Chem. Int. Ed. Engl.* **2016**, *55*, 2356–60.
- [2] J. Tykvart, J. Schimer, J. Barinková, P. Pachel, L. Postová Slavetínská, P. Majer, J. Konvalinka, P. Šácha, *Bioorg. Med. Chem.* **2014**, *22*, 4099–4108.